Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta + Envafolimab + Suvemcitug with chemotherapy as neoadjuvant treatment for operable penile cancer
ChiCTR2600124278Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of cetuximab, envafolimab and suvemcitug in penile squamous cell carcinoma (PSCC) (3 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Pathological complete response (pCR) and Penis-sparing surgery completion rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
cetuximabenvafolimabsuvemcitug
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2600124278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124278.